LEE011F
Drug
Novartis Pharma AG
Total Payments
$14,384
Transactions
5
Doctors
1
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $4,464 | 2 | 1 |
| 2017 | $9,920 | 3 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $14,384 | 5 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| CLEE011F2301 | Novartis Pharma AG | $14,384 | 1 |
Top Doctors Receiving Payments for LEE011F
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Clinical Cardiac Electrophysiology | Wynnewood, PA | $14,384 | 5 |
Ad
Manufacturing Companies
- Novartis Pharma AG $14,384
Product Information
- Type Drug
- Total Payments $14,384
- Total Doctors 1
- Transactions 5
About LEE011F
LEE011F is a drug associated with $14,384 in payments to 1 healthcare providers, recorded across 5 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharma AG.
Payment data is available from 2017 to 2018. In 2018, $4,464 was paid across 2 transactions to 1 doctors.
The most common payment nature for LEE011F is "Unspecified" ($14,384, 100.0% of total).
LEE011F is associated with 1 research study, including "CLEE011F2301" ($14,384).